Ashland targets $1.905B-$1.975B sales and $405M-$435M adjusted EBITDA in fiscal 2027 as CapEx rises to up to $140M (NYSE:ASH)
Ashland (ASH) forecasts fiscal 2027 sales of $1.905B-$1.975B and adjusted EBITDA of $405M-$435M, with CapEx up to $140M. CEO Guillermo Novo reported strong Q4 2026 performance, with Life Sciences sales up 4% and Personal Care sales up 8%.
How this was made
The 30-second read
Why it matters
The new FY2027 guidance provides the first forward‑looking numbers for the next fiscal year, offering a basis for valuation adjustments.
Market read
Fresh FY2027 guidance for a mid‑cap industrial firm; relevant for sector analysts and traders with exposure to specialty chemicals.
What to watch
Potential upside from upcoming specialty product launches not reflected in the guidance.
Background
Ashland is a specialty chemicals company with diversified segments including Life Sciences and Personal Care.
Ticker impact
Ashland disclosed FY2027 sales guidance of $1.905B-$1.975B and adjusted EBITDA of $405M-$435M, plus up to $140M CapEx, a fresh corporate forecast.
likely modest upside if guidance exceeds consensus, otherwise limited pressure
The numbers are new and material, yet no clear beat or miss relative to prior estimates; market reaction will hinge on analyst expectations.
Market effects
Sets a benchmark for specialty chemicals peers' FY2027 outlooks.
Limited to U.S. and European markets where Ashland operates.
Low global impact; primarily affects investors tracking mid‑cap industrial stocks.
Counterpoint
If analysts expected higher growth, the guidance could be seen as a disappointment, prompting a sell‑off.
Key entities
- ExecutiveGuillermo Novo
Chairman & CEO of Ashland who presented the guidance.
